Ketamine Dosing and Administration: A Complete Clinical Guide

Pharmacokinetic Foundations

Rational ketamine dosing requires a firm understanding of the drug's pharmacokinetic properties. Ketamine is a phencyclidine-derivative dissociative anesthetic with a molecular weight of 237.7 daltons. Its moderate lipophilicity facilitates rapid blood-brain barrier penetration, while its relatively low plasma protein binding (12 to 47 percent, primarily to alpha-1-acid glycoprotein and albumin) means that the majority of circulating drug is pharmacologically available. For a detailed exploration of these properties, see the pharmacokinetics overview.

Absorption, Distribution, Metabolism, Elimination

Absorption: Bioavailability varies dramatically by route of administration -- from 100 percent (intravenous) to approximately 17 percent (oral) -- making route selection one of the most consequential dosing decisions.

Distribution: Ketamine follows a two- or three-compartment pharmacokinetic model. The volume of distribution at steady state is approximately 3 to 5 L/kg, reflecting extensive tissue uptake. Rapid redistribution from brain tissue to peripheral compartments (distribution half-life of 10 to 15 minutes) accounts for the brief duration of acute psychoactive effects following a single bolus, despite a longer terminal elimination half-life.

Metabolism: Hepatic biotransformation via CYP3A4 and CYP2B6 produces norketamine (approximately one-third the potency of the parent compound) as the primary metabolite. Norketamine is further hydroxylated to hydroxynorketamine (HNK) isomers, particularly (2R,6R)-HNK, which has attracted research interest for potential AMPA receptor-mediated antidepressant activity independent of NMDA blockade.

Elimination: Terminal elimination half-life is approximately 2 to 3 hours for racemic ketamine. S-ketamine is cleared slightly faster than R-ketamine. Norketamine has a half-life of approximately 5 to 8 hours, and HNK metabolites may persist for 12 hours or longer. Hepatic clearance is high (12 to 20 mL/kg/min), classifying ketamine as a flow-dependent drug -- meaning that conditions reducing hepatic blood flow can significantly prolong its effects.

Enantiomer Pharmacology

Ketamine is commercially available as a racemic mixture of S(+)-ketamine (esketamine) and R(-)-ketamine (arketamine). Key differences relevant to dosing:

• NMDA receptor affinity: Esketamine has approximately 3- to 4-fold higher affinity for the NMDA receptor than arketamine
• Clearance: Esketamine is cleared approximately 20 percent faster than arketamine
• Dosing implications: When using esketamine (as in Spravato), lower absolute doses produce comparable receptor occupancy to higher doses of racemic ketamine

For a detailed comparison of enantiomer-specific dosing considerations, see esketamine vs. racemic dosing.

The Subanesthetic Dose Range

The term "subanesthetic" refers to doses below the threshold required for general anesthesia. For intravenous ketamine, the anesthetic induction dose is typically 1 to 2 mg/kg administered as a bolus. The subanesthetic dose range used in psychiatric and pain practice is substantially lower:

Clinical: The 0.5 mg/kg IV dose administered over 40 minutes has become the de facto standard for antidepressant applications because it was used in the landmark Zarate et al. (2006) trial and has been replicated across dozens of subsequent studies. However, this dose was selected empirically for the original trial, and the optimal antidepressant dose has not been definitively established through systematic dose-finding studies. The dose-response relationship for antidepressant efficacy remains an active area of investigation.

Weight-Based Dosing Principles

Standard Weight-Based Calculation

Ketamine dosing for psychiatric and analgesic indications is universally expressed on a weight basis (mg/kg). For a standard IV antidepressant infusion:

Dose = 0.5 mg/kg x patient weight (kg) administered over 40 minutes

For a 70-kg patient, this yields a total dose of 35 mg. For a 90-kg patient, the total dose would be 45 mg. Detailed calculation tables and clinical considerations are provided in weight-based dosing guidelines.

Which Weight to Use?

The question of which body weight metric to use for dosing becomes clinically significant in obese patients. Options include:

• Total body weight (TBW): The patient's actual measured weight. Using TBW in obese patients may produce higher-than-intended plasma concentrations because ketamine's volume of distribution, while influenced by adipose tissue, does not increase proportionally with total body mass.
• Ideal body weight (IBW): Calculated based on height and sex (e.g., Devine formula). Dosing by IBW may underestimate the appropriate dose for very obese patients.
• Adjusted body weight (ABW): IBW + 0.4 x (TBW - IBW). This compromise metric accounts for partial distribution into adipose tissue and is increasingly recommended for ketamine dosing in obesity.

Clinical recommendation: For patients with BMI >30, most experts recommend dosing based on adjusted body weight or ideal body weight rather than total body weight. This approach balances adequate drug exposure against the risk of excessive dosing and exaggerated side effects.

Maximum Dose Considerations

While weight-based dosing is standard, some clinicians employ dose caps to limit absolute exposure:

• A common maximum total dose for IV antidepressant infusion is 40 to 50 mg, regardless of body weight
• This ceiling is not evidence-based but reflects conservative practice, particularly for patients weighing >100 kg
• Individual titration based on clinical response and tolerability is preferable to rigid caps

Dose-Response Relationships

Antidepressant Dose-Response

The relationship between ketamine dose and antidepressant efficacy is one of the most important unresolved questions in the field. Available evidence suggests a non-linear, potentially biphasic dose-response curve. For detailed analysis, see dose-response relationships.

Key findings from dose-ranging studies:

• Fava et al., 2018 (NIMH): A large, multicenter randomized trial compared IV ketamine at 0.1, 0.2, 0.5, and 1.0 mg/kg with midazolam (active placebo) in 99 patients with TRD. While all ketamine doses showed numerical superiority to midazolam, only the 0.5 and 1.0 mg/kg doses reached statistical significance. Notably, the 1.0 mg/kg dose did not produce greater antidepressant effect than 0.5 mg/kg but did produce significantly more dissociation and hemodynamic changes.
• Su et al., 2017: Compared 0.2 and 0.5 mg/kg IV ketamine in a double-blind trial and found that both doses produced antidepressant effects, with the 0.5 mg/kg dose showing a trend toward greater efficacy.
• Singh et al., 2016: The intranasal esketamine dose-ranging study tested 28, 56, and 84 mg doses. All three produced significant antidepressant effects, with no clear dose-response gradient for efficacy but a clear dose-response relationship for side effects.

Clinical interpretation: The available evidence suggests that antidepressant efficacy plateaus at or near the standard 0.5 mg/kg IV dose, while side effects continue to increase with higher doses. This argues against dose escalation beyond 0.5 mg/kg for most patients and supports exploration of lower doses (0.2 to 0.4 mg/kg) for patients who are sensitive to dissociative or hemodynamic effects.

Side Effect Dose-Response

In contrast to the plateau observed for antidepressant efficacy, the dose-response relationship for adverse effects is more linear:

• Dissociation: Increases progressively with dose. At 0.1 mg/kg, dissociation is minimal or absent; at 0.5 mg/kg, it is typically moderate; at 1.0 mg/kg, it may approach anesthetic-level dissociation.
• Blood pressure elevation: Increases in a dose-dependent manner. Systolic blood pressure typically rises 15 to 25 mmHg at 0.5 mg/kg; elevations may be more pronounced at higher doses.
• Nausea: More common at higher doses, though substantial interindividual variability exists.
• Psychotomimetic symptoms: Perceptual disturbances and disorganized thinking increase with dose and approach clinical significance at the upper end of the subanesthetic range.

Warning: The combination of a flat efficacy curve and a steep side-effect curve at doses above 0.5 mg/kg argues strongly against empiric dose escalation in non-responders. Patients who do not respond to 0.5 mg/kg IV ketamine are unlikely to respond to higher doses and should be assessed for alternative strategies including route change, augmentation, or treatment reassessment.

Route-Specific Dosing Protocols

Intravenous (IV) Infusion

The IV route provides the most precise dose control and the largest evidence base for psychiatric applications. See IV infusion protocols for complete clinical guidance.

Standard antidepressant protocol:

• Dose: 0.5 mg/kg over 40 minutes
• Preparation: Dilute calculated dose in 50 to 100 mL normal saline
• Infusion rate: Volume / 40 minutes (e.g., for 35 mg in 100 mL, rate = 2.5 mL/min or 150 mL/hr)
• Monitoring: Vital signs (BP, HR, SpO2) every 10 to 15 minutes during infusion and every 15 to 30 minutes for 2 hours post-infusion

Titration approach for sensitive patients:
Some clinicians employ a stepped titration for patients who are anxiety-prone, elderly, or naive to ketamine:

• Session 1: 0.3 mg/kg over 40 minutes
• Session 2: 0.4 mg/kg over 40 minutes (if tolerated)
• Session 3 onward: 0.5 mg/kg over 40 minutes (standard dose)

Infusion rate adjustments:
The infusion rate can be temporarily reduced or paused if the patient experiences:

• Severe dissociation causing distress
• Systolic blood pressure >180 mmHg or diastolic >110 mmHg
• Significant nausea unresponsive to antiemetic pretreatment
• Oxygen saturation <92 percent

Intramuscular (IM) Injection

IM ketamine is used primarily in emergency settings and pain clinics. Bioavailability of approximately 93 percent means that IM doses can be calculated as roughly equivalent to IV doses.

Typical dosing:

• Antidepressant/anti-suicidal: 0.5 mg/kg as a single injection
• Analgesic: 0.25 to 0.5 mg/kg
• Peak effect: 15 to 30 minutes post-injection
• Injection site: Deltoid or vastus lateralis muscle

Advantages: No IV access required, rapid administration. Limitations: Less precise titration, variable absorption, injection site pain.

Sublingual Administration

Sublingual delivery partially bypasses first-pass hepatic metabolism, achieving bioavailability of approximately 25 to 30 percent. See sublingual and oral protocols for detailed clinical guidance.

Typical dosing:

• Starting dose: 50 to 100 mg sublingual (equivalent to approximately 12.5 to 30 mg systemic exposure based on 25-30 percent bioavailability)
• Therapeutic range: 100 to 300 mg sublingual for antidepressant indications
• Formulations: Compounded troches, rapidly dissolving tablets, or liquid solutions
• Hold time: Patients are instructed to hold the dissolved formulation under the tongue for 10 to 15 minutes, then spit out residual saliva (spit protocol) to minimize oral absorption and gastrointestinal side effects

Bioavailability optimization: Several factors influence sublingual absorption and are addressed in oral bioavailability optimization:

• Formulation pH and buffer composition
• Hold time under the tongue (longer hold time = greater absorption)
• Mucosal blood flow (dehydration, vasoconstriction reduce absorption)
• Spit vs. swallow protocol (spitting reduces GI exposure but slightly reduces total bioavailability)

Clinical: When converting from IV to sublingual dosing, a common clinical approach is to target equivalent systemic exposure. For example, a patient receiving 35 mg IV (0.5 mg/kg for a 70-kg patient with 100 percent bioavailability) would require approximately 120 to 140 mg sublingual (at 25 to 30 percent bioavailability) to achieve comparable peak plasma levels, though the pharmacokinetic profile (time to peak, duration) will differ.

Oral Administration

Oral ketamine has the lowest bioavailability (approximately 17 percent, range 16 to 24 percent) due to extensive first-pass hepatic metabolism. Oral dosing produces proportionally higher norketamine-to-ketamine ratios, which may have clinical implications given norketamine's pharmacological activity.

Typical dosing:

• Starting dose: 0.5 mg/kg orally (approximately equivalent to 0.085 mg/kg systemically)
• Therapeutic range: 0.5 to 3.0 mg/kg orally for depression
• Common doses: 50 to 200 mg orally, administered one to three times per week
• Peak effect: 30 to 60 minutes
• Duration of subjective effects: 1 to 2 hours

Clinical considerations: The higher norketamine ratios produced by oral administration may contribute to a distinct pharmacological profile. Some patients who do not respond to oral ketamine may respond to routes that produce higher parent-to-metabolite ratios, and vice versa.

Intranasal Administration

Compounded racemic ketamine:

• Typical dose: 50 to 100 mg per session (divided across multiple sprays to each nostril)
• Bioavailability: 25 to 50 percent (highly variable)
• Standardization challenges: Compounded nasal sprays vary in formulation, spray volume, and delivery device

FDA-approved esketamine (Spravato):
The intranasal esketamine protocol follows the FDA-approved prescribing information:

• Induction (weeks 1-4): 56 mg or 84 mg, administered twice weekly
• Maintenance (weeks 5-8): 56 mg or 84 mg, administered once weekly
• Maintenance (week 9 onward): 56 mg or 84 mg, administered every 2 weeks or once weekly
• Each device delivers 28 mg in two sprays (one per nostril); 56 mg requires two devices, 84 mg requires three devices

Starting dose selection: The prescribing information recommends starting at 56 mg and increasing to 84 mg based on efficacy and tolerability, though some clinicians begin at 84 mg based on trial data showing comparable efficacy across doses. Patients aged 65 and older should start at 28 mg.

Titration Strategies

Initial Dose Selection

The choice of starting dose should consider:

1. Patient weight: Use adjusted body weight for BMI >30
2. Age: Consider dose reduction (0.25 to 0.4 mg/kg IV) for patients over 65
3. Hepatic function: Reduce dose for hepatic impairment (see below)
4. Medication interactions: CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) may increase ketamine exposure; CYP3A4 inducers (carbamazepine, phenytoin, rifampin) may decrease it
5. Benzodiazepine use: Concurrent benzodiazepines may attenuate ketamine's antidepressant effects through GABAergic mechanisms; consider tapering if clinically feasible
6. Anxiety about treatment: Highly anxious patients may benefit from a lower initial dose
7. Prior ketamine experience: Patients who have tolerated prior treatments may begin at standard dosing

Dose Adjustment for Non-Response

For patients who do not respond to the standard 0.5 mg/kg IV dose after three to four infusions:

Step 1 -- Rule out confounders:

• Verify medication compliance (particularly concurrent antidepressants)
• Assess for benzodiazepine or opioid use that may attenuate response
• Confirm accurate weight-based dosing calculation
• Screen for active substance use or medical conditions

Step 2 -- Consider modest dose escalation:

• Increase to 0.75 mg/kg IV over 40 minutes with enhanced monitoring
• Evidence for benefit above 0.5 mg/kg is limited; proceed cautiously

Step 3 -- Consider route change:

• Some patients may respond better to a different route (e.g., IM vs. IV) due to different pharmacokinetic profiles
• Intranasal esketamine may provide benefit in patients who do not respond to racemic IV ketamine, and vice versa

Step 4 -- Consider augmentation:

• Combination therapy protocols pairing ketamine with lithium, lamotrigine, or structured psychotherapy
• Timing of concurrent psychotherapy to coincide with the post-infusion neuroplastic window

Step 5 -- Reassess indication and diagnosis:

• Confirm the primary diagnosis
• Consider whether the patient is an appropriate candidate for alternative interventions (ECT, TMS, VNS)

Dose Reduction for Side Effects

If adverse effects are dose-limiting:

• Dissociation: Reduce dose by 20 percent (e.g., 0.4 mg/kg instead of 0.5 mg/kg) or extend infusion duration (60 minutes instead of 40 minutes). Slower infusion rate reduces peak plasma concentration without substantially changing total exposure.
• Hypertension: Consider pre-treatment with clonidine (0.1 to 0.2 mg oral) or reduce dose. Evaluate baseline antihypertensive regimen optimization. See cardiovascular monitoring for detailed protocols.
• Nausea: Pre-treat with ondansetron (4 to 8 mg IV or oral) 30 minutes before infusion. Reduce dose if nausea persists despite antiemetic prophylaxis.
• Anxiety/agitation: Ensure optimal set and setting. Consider low-dose midazolam pre-treatment (0.5 to 1 mg IV), though this may attenuate antidepressant effects.

Special Population Dosing

Geriatric Patients

Age-related changes in pharmacokinetics and pharmacodynamics necessitate dosing modifications for older adults. See geriatric ketamine considerations for a comprehensive review.

Pharmacokinetic changes:

• Reduced hepatic blood flow and CYP450 enzyme activity slow ketamine clearance
• Decreased albumin and alpha-1-acid glycoprotein may increase free drug fraction
• Reduced lean body mass alters volume of distribution
• Increased sensitivity to hemodynamic effects

Dosing recommendations:

• Start at 0.25 to 0.35 mg/kg IV over 40 minutes
• Titrate upward in increments of 0.05 to 0.1 mg/kg based on response and tolerability
• Maximum recommended dose: 0.5 mg/kg IV, with cautious titration
• For intranasal esketamine (Spravato): Start at 28 mg per FDA labeling
• Extended post-infusion monitoring (minimum 2 hours) is recommended

Pediatric and Adolescent Patients

The evidence base for ketamine in pediatric depression is limited, and use in patients under 18 is considered investigational. See pediatric dosing considerations.

Available evidence:

• Small open-label studies have used doses of 0.5 mg/kg IV in adolescents aged 13 to 17 with TRD
• Pharmacokinetic modeling suggests that adolescents may have slightly faster clearance than adults
• Intranasal esketamine (Spravato) is not FDA-approved for patients under 18
• Risk-benefit analysis must weigh the severity of the condition against limited safety data

Warning: Ketamine treatment in patients under 18 should be considered only in the context of severe, treatment-resistant illness under the supervision of experienced child and adolescent psychiatrists, ideally within research protocols or at academic medical centers with appropriate expertise and monitoring capabilities.

Hepatic Impairment

Given ketamine's high hepatic clearance, liver impairment significantly affects drug disposition. Detailed guidance is available in renal and hepatic dose adjustments.

Mild hepatic impairment (Child-Pugh A):

• Start at standard dose (0.5 mg/kg IV) with careful monitoring
• Monitor for prolonged effects
• Consider extended observation period

Moderate hepatic impairment (Child-Pugh B):

• Reduce starting dose to 0.25 to 0.35 mg/kg IV
• Expect prolonged elimination half-life
• Longer monitoring period required (minimum 3 hours)
• Check baseline and periodic liver function tests

Severe hepatic impairment (Child-Pugh C):

• Generally contraindicated due to unpredictable pharmacokinetics and risk of hepatotoxicity
• If treatment is deemed essential, use lowest possible dose with extended monitoring and hepatology consultation

Renal Impairment

Ketamine itself is not primarily renally eliminated, but hydroxylated metabolites and glucuronide conjugates are excreted by the kidneys. In severe renal impairment:

• Parent drug clearance is not substantially affected
• Metabolite accumulation may occur, though the clinical significance is uncertain
• Standard dosing can generally be used with monitoring
• Caution in patients on dialysis; timing of treatment relative to dialysis sessions should be considered

Obesity

As discussed in the weight-based dosing section:

• Use adjusted body weight (ABW) for BMI >30
• Formula: ABW = IBW + 0.4 x (TBW - IBW)
• Consider total dose caps (40 to 50 mg for IV antidepressant infusion) as a safety measure
• Monitor for both under-dosing (using IBW exclusively) and over-dosing (using TBW)

Drug Interactions Affecting Dosing

Several drug-drug interactions have clinically relevant implications for ketamine dosing:

CYP3A4 Inhibitors

Strong inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) reduce ketamine clearance and may increase plasma levels by 30 to 50 percent. Consider:

• Dose reduction of 20 to 30 percent when strong CYP3A4 inhibitors cannot be discontinued
• Extended monitoring for prolonged effects
• Awareness that norketamine formation will also be reduced

CYP3A4 Inducers

Strong inducers (carbamazepine, phenytoin, phenobarbital, rifampin, St. John's wort) accelerate ketamine metabolism and may reduce efficacy. Consider:

• Dose increase of 20 to 30 percent may be necessary
• Monitoring for reduced clinical response
• Awareness that norketamine formation will be increased

Benzodiazepines

Multiple studies suggest that concurrent benzodiazepine use may attenuate ketamine's antidepressant effects, possibly through enhancement of GABAergic inhibition that opposes ketamine's disinhibition mechanism. Clinical implications:

• Document benzodiazepine use at baseline
• Consider benzodiazepine taper before initiating ketamine, if clinically feasible
• Do not abruptly discontinue benzodiazepines in dependent patients
• If taper is not possible, proceed with standard dosing and interpret non-response cautiously

Lamotrigine

Lamotrigine, an anticonvulsant that reduces glutamate release, has theoretical potential to counteract ketamine's mechanism. Some studies have found reduced ketamine efficacy in patients taking lamotrigine, though findings are inconsistent. Consider risk-benefit of continuation versus discontinuation.

Opioids

The interaction between opioids and ketamine is complex. While ketamine has opioid-sparing analgesic properties, chronic opioid use may alter glutamate system function and potentially affect ketamine response. The naltrexone controversy (whether opioid receptor activation is necessary for ketamine's antidepressant effect) remains unresolved. See opioid system interactions for detailed analysis.

For a comprehensive review of medication interactions, see ketamine drug interactions.

Monitoring Protocols

Pre-Treatment Assessment

Before initiating ketamine therapy, the following assessments are recommended:

• Medical: Complete vital signs, cardiovascular risk assessment, hepatic function panel, thyroid function, basic metabolic panel
• Psychiatric: Validated depression rating scale (MADRS, PHQ-9), suicidal ideation assessment (C-SSRS), substance use screening, psychosis screening
• Documentation: Medication list with attention to CYP3A4 modulators, benzodiazepines, and lamotrigine; allergy history; prior ketamine exposure history

During-Treatment Monitoring

Standard monitoring during IV ketamine infusion, as detailed in monitoring and assessment:

Post-Treatment and Between-Session Monitoring

• Vital sign stability: Confirm return to within 20 percent of baseline before discharge
• Functional assessment: Patient must be ambulatory, oriented, and able to engage in conversation
• Driving restriction: No driving or operating heavy machinery for remainder of day
• Depression assessment: PHQ-9 or MADRS before each subsequent session
• Side effect tracking: Standardized side effect checklist at each visit
• Long-term safety monitoring: Liver function tests every 3 to 6 months for patients on maintenance; urinalysis if urological symptoms develop; cognitive assessment at baseline and periodically

Maintenance Dosing Strategies

Individually Titrated Maintenance

After completing an acute series (typically six infusions over two to three weeks), patients who demonstrate response transition to maintenance therapy. The approach to maintenance dosing is described in detail in maintenance infusion protocols.

Interval determination: The optimal maintenance interval is determined individually by monitoring symptom recurrence:

• Begin with sessions every 2 weeks after the acute series
• If symptoms remain well-controlled at 2 weeks, extend to every 3 weeks
• Continue extending by 1 week until the minimum effective frequency is identified
• If symptoms recur before the next scheduled session, shorten the interval
• Typical maintenance intervals range from every 2 weeks to every 6 weeks

Dose during maintenance: The dose that produced response during the acute series is typically maintained. Dose reduction during maintenance has not been systematically studied and is generally not recommended unless side effects emerge.

Route Transition for Maintenance

Some treatment models use IV ketamine for acute stabilization, then transition to sublingual or oral formulations for maintenance. This approach prioritizes the efficacy and evidence base of IV for acute treatment while leveraging the convenience and cost advantages of oral/sublingual routes for long-term maintenance.

Transition protocol (example):

1. Complete IV acute series (6 infusions)
2. Begin sublingual or oral ketamine at equivalent systemic dose (adjusted for bioavailability)
3. Continue monitoring with validated depression scales
4. If relapse occurs on oral/sublingual, return to IV for re-stabilization

Discontinuation and Relapse Prevention

No standardized ketamine discontinuation protocol exists. Ketamine does not produce physical dependence at clinical doses in the manner of benzodiazepines or opioids, so abrupt discontinuation does not cause a withdrawal syndrome. However, patients may experience symptom recurrence (relapse of depression) within days to weeks of stopping treatment.

A reasonable approach to planned discontinuation:

• Gradually extend the interval between maintenance sessions
• Ensure that concurrent antidepressant medication and psychotherapy are optimized before attempting discontinuation
• Monitor closely for relapse in the weeks following the final session
• Establish a plan for rapid re-initiation if relapse occurs

Dose Calculations: Clinical Reference Tables

IV Dose by Body Weight (0.5 mg/kg)

Note: All calculations assume dilution to 100 mL total volume. Infusion rate is volume-based (100 mL / 40 min = 150 mL/hr). Drug concentration varies by dose.

Sublingual Dose Equivalence (Estimated)

Clinical: These equivalence calculations are approximate. Sublingual bioavailability varies significantly between individuals and between formulations. Route conversion should always be accompanied by close clinical monitoring, and doses should be titrated based on individual response rather than relying solely on pharmacokinetic calculations.

Conclusion

Rational ketamine dosing integrates pharmacokinetic principles with clinical evidence and individual patient factors. The standard IV dose of 0.5 mg/kg over 40 minutes remains the best-supported starting point for antidepressant applications, but clinicians must be prepared to adjust based on patient weight characteristics, age, organ function, concurrent medications, and individual response patterns. The expanding repertoire of routes and formulations offers flexibility but demands attention to the substantial bioavailability differences that make direct dose comparisons between routes inherently complex.

Careful monitoring, systematic outcome assessment, and individualized titration are the hallmarks of expert ketamine dosing. As the evidence base continues to mature through dose-ranging studies, biomarker research, and long-term safety data, dosing recommendations will continue to be refined.

References

• Zarate CA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 2006 -- Established the 0.5 mg/kg over 40 minutes paradigm that remains the standard of care
• Fava M et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression. Molecular Psychiatry, 2018 -- The largest dose-finding study comparing 0.1, 0.2, 0.5, and 1.0 mg/kg IV ketamine
• Su TP et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology, 2017 -- Dose comparison of 0.2 vs. 0.5 mg/kg IV ketamine for depression
• Singh JB et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. American Journal of Psychiatry, 2016 -- Dose-ranging study informing intranasal esketamine development
• Ketamine pharmacokinetics. National Library of Medicine, DailyMed -- FDA-approved prescribing information and pharmacokinetic data
• Spravato (esketamine) prescribing information. U.S. Food and Drug Administration, 2019 -- Official FDA prescribing information including dosing schedule
• Zanos P et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacological Reviews, 2018 -- Comprehensive review of ketamine and metabolite pharmacology
• Clements JA et al. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. Journal of Pharmaceutical Sciences, 1982 -- Foundational pharmacokinetic study establishing bioavailability across routes
• Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? Journal of Clinical Psychiatry, 2017 -- Clinical review synthesizing dosing evidence across parameters
• World Health Organization. Model List of Essential Medicines, 23rd Edition, 2023 -- WHO recognition of ketamine as an essential medicine for anesthesia and analgesia
• Ketamine. Mayo Clinic Drug Information -- Patient-accessible overview of ketamine pharmacology and safety
• NIH National Library of Medicine. Ketamine compound summary. PubChem -- Chemical and pharmacological reference data